Novo Struggles In Japan, Sanofi Struggles With Distributors: Emerging Markets Earnings Roundup (Part 7)
This article was originally published in PharmAsia News
Both Novo Nordisk and Sanofi had a bumpy start of the year in Asia and emerging markets. Novo saw insulin sales decline in Japan and Korea, while Sanofi grew only 6.5% in emerging markets, well below the company’s long-term guidance of double-digit growth.
You may also be interested in...
Sanofi plans to split its commercial organization into two units as the French drug giant starts to emerge from its patent cliff with a return to growth and a renewed focus on new diabetes therapies.
FDA is requesting data from a dedicated cardiovascular outcomes trial before approving the ultra-long-acting insulins Tresiba and Ryzodeg. News of the regulatory setback caused a 13% drop in the company’s stock price on Feb. 11.
Sanofi-Aventis has gained a leadership position in China's OTC cough/cold market with its $520.6 million acquisition of BMP Sunstone, the latest in the global pharma's parade of consumer health buys